Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (Diabetologia, 10.1007/s00125-016-3956-x)

Naveed Sattar; James McLaren; Søren L. Kristensen; David Preiss; John J. McMurray

ArticleOPEN ACCESS

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (Diabetologia, 10.1007/s00125-016-3956-x)

Diabetologia

DOI: 10.1007/s00125-016-3987-3

7Citations

49Readers

Get full text

Abstract

Unfortunately an error occurred during the typesetting of Fig. 1 which meant that the arrow in the ‘KIDNEY: SGLT2 inhibition’ text box was incorrectly orientated. The arrow is corrected in the version of the figure shown overleaf.

Cite

CITATION STYLE

APA

Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016, July 1). Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (Diabetologia, 10.1007/s00125-016-3956-x). Diabetologia. Springer Verlag. https://doi.org/10.1007/s00125-016-3987-3

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? (Diabetologia, 10.1007/s00125-016-3956-x)

Abstract

Cite

Register to see more suggestions